UV1 is named as an intervention in 2 current clinical trials in our Denmark and Norway registers. 1 is recruiting patients now. All registered phases are Phase 2. The sponsor with the most trials is Nordic Society of Gynaecological Oncology - Clinical Trials Unit (1). The most-studied condition is Ovarian Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer
NCT05344209 · ClinicalTrials.gov ↗ · Oncology, NSCLC Stage IV, NSCLC, Stage III
|
Phase 2 | Recruiting | Vestre Viken Hospital Trust | Norway |
|
Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer
NCT04742075 · ClinicalTrials.gov ↗ · Ovarian Cancer
|
Phase 2 | Active, closed | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | Denmark |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Nordic Society of Gynaecological Oncology - Clinical Trials Unit | 1 |
| Vestre Viken Hospital Trust | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Denmark | 1 | 0 |
| Clinical trials in Norway | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Denmark and Norway registers name UV1 as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in Norway. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Nordic Society of Gynaecological Oncology - Clinical Trials Unit (1) and Vestre Viken Hospital Trust (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how UV1 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how UV1 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists UV1 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.